http://orcid.org/0000-0001-8650-5066
![Sample our Health and Social Care journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5938/TOC-Subject-Sample-2021-Health-Social-Care.jpg"})
ABSTRACT
Objective: Over the two years following the 2012 introduction of CMS’s National Partnership, combined rates of schizophrenia, Tourette’s, and Huntington’s in US long-stay residents increased 12%. We evaluated trends in reporting of these diagnoses for the subgroup of long-stay residents on antipsychotics.
Methods: Retrospective analysis of Virginia Medicaid claims identified annual utilization rates of psychiatric diagnoses for long-stay seniors on antipsychotics. Chi-square analysis compared rates for the year before March, 2012 with the same 12-month period 1 year later. A 5-year pre-existing baseline rate was also obtained.
Results: Diagnosis rates for 2011 were unchanged from baseline. Comparing 2011 with 2013, diagnoses rates for schizophrenia, Tourette’s, and Huntington’s combined increased 40% (p < .0001), primarily because schizophrenia reporting nearly doubled (p < .0001).
Conclusions: For long-stay seniors on antipsychotics, reporting of schizophrenia, Tourette’s, and Huntington’s began increasing in 2012 and at almost triple the rate CMS described for the general long-stay population. The increased reporting of these diagnoses described by CMS since 2012 appears to be new and concentrated in residents on antipsychotics
Clinical Implications: Since antipsychotics prescribed for schizophrenia, Tourette’s, and Huntington’s are excluded from quality-measure auditing, apparent reductions in inappropriate long-stay antipsychotic use since the National Partnership may be exaggerated.
Funding
Supported in part by Commonwealth of Virginia’s Alzheimer’s and Related Diseases Research Award Fund [Award 15-2], Virginia Center on Aging, School of Allied Health Professions, Virginia Commonwealth University.